Stock Research: medmix

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

medmix

SWX:MEDX CH1129677105
34
  • Value
    32
  • Growth
    7
  • Safety
    Safety
    98
  • Combined
    41
  • Sentiment
    40
  • 360° View
    360° View
    34
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Medmix AG is a Switzerland-based company primarily engaged in manufacturing of healthcare, dental and beauty devices. The Company operates through two reportable segments: Healthcare along with Consumer and Industrial. Healthcare segment includes design and production of high-precision delivery devices and services within drug delivery, surgery and dental markets. Products include injection pens, surgical delivery devices focusing on trauma bone repair and wound healing tissue treatment and mixing, filling and delivery device systems for the dental consumable industry. Consumer and Industrial segment consists of design and production of high precision delivery devices within industry business unit, this includes adhesives used in construction, electronics, automotive, aerospace and various industries, and consumer markets such as beauty and other microbrush applications.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 34 (better than 34% compared with alternatives), overall professional sentiment and financial characteristics for the stock medmix are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for medmix. Only the consolidated Value Rank has an attractive rank of 98, which means that the share price of medmix is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 98% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 7, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 32, meaning the company has a riskier financing structure than 68% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 60% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 40. ...read more

more
Index
SPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
98 94 97 73
Growth
7 40 31 23
Safety
Safety
32 32 37 4
Sentiment
40 20 19 1
360° View
360° View
34 39 37 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
81 73 74 76
Opinions Change
50 50 50 4
Pro Holdings
n/a 18 3 12
Market Pulse
19 7 12 4
Sentiment
40 20 19 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
98 94 97 73
Growth
7 40 31 23
Safety Safety
32 32 37 4
Combined
41 66 56 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
72 61 66 49
Price vs. Earnings (P/E)
87 81 70 51
Price vs. Book (P/B)
90 91 92 36
Dividend Yield
96 94 95 97
Value
98 94 97 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
26 58 35 47
Profit Growth
4 19 10 24
Capital Growth
25 82 39 33
Stock Returns
65 22 75 45
Growth
7 40 31 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
28 24 18 18
Refinancing
79 64 77 7
Liquidity
12 23 37 23
Safety Safety
32 32 37 4

Similar Stocks

Discover high‑ranked alternatives to medmix and broaden your portfolio horizons.

ALSO

SWX:ALSN
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

SoftwareONE Holding

SWX:SWON
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Drägerwerk

XTRA:DRW3
Country: Germany
Industry: Health Care Equipment
Size: Medium
Full Stock Analysis

Smith & Nephew

LSE:SN.
Country: United Kingdom
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.